Science - CRS. Experts. Early Phase.

Bioequivalence of macitentan and tadalafil given as fixed-dose combination or single-component tablets in healthy subjects.

. 30. Januar 2023

bioequivalence fixed-dose combination macitentan pulmonary arterial hypertension tadalafil

Midazolam microdosing applied in early clinical development for drug-drug interaction assessment.

. 30. Januar 2023

CYP3A drug-drug interactions early clinical development microdosing midazolam

The effects of vilaprisan on the pharmacodynamics and pharmacokinetics of a combined oral contraceptive – A randomized controlled trial.

. 30. Januar 2023

interaction ombined oral contraceptive selective progesterone receptor modulator

Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton’s tyrosine kinase, in Phase I clinical trials in healthy volunteers.

. 30. Januar 2023

A practical approach to the clinical challenges in initiation of basal insulin therapy in people with type 2 diabetes.

. 30. Januar 2023

Diabetic Macular Edema in Diabetological Practices.

. 30. Januar 2023

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.

. 30. Januar 2023

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T-cell responses.

. 30. Januar 2023

Highly purified human menopausal gonatrophin (HP-hMG, Menopur) as ready-to-use solution for injection in pre-filled pen is bioequivalent to HP-hMG powder for reconstitution.

. 30. Januar 2023

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans.

. 30. Januar 2023

First evaluation of the safety, pharmacokinetics and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor Xia.

. 30. Januar 2023

anticoagulant factor XI hemostasis phase 1 thrombosis

Effect of Renal Function Impairment on the Pharmacokinetics, Safety, and Tolerability of the Iminosugar Sinbaglustat.

. 30. Januar 2023

dose-adjustment iminosugar pharmacokinetics renal function impairment sinbaglustat

CRO Leadership Awards 2019

CRS is proud to be recognised again by pharma companies worldwide as a leading CRO with regard to: capabilities, compatibility, quality and reliability.

European Biotechnology Guide

Find CRS’s company profile in the European Biotechnology Science Industry Guide, volume 9 2019.

EcoVadis – CSR Rating

Based on the CSR rating by EcoVadis in 2022 CRS has been granted Silver Recognition Level.